Compare VTEX & ANNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VTEX | ANNX |
|---|---|---|
| Founded | 1999 | 2011 |
| Country | Cayman Islands | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 755.3M | 873.3M |
| IPO Year | 2019 | 2020 |
| Metric | VTEX | ANNX |
|---|---|---|
| Price | $3.60 | $4.19 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 6 |
| Target Price | $5.97 | ★ $16.50 |
| AVG Volume (30 Days) | 651.9K | ★ 2.8M |
| Earning Date | 05-07-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $12.78 | N/A |
| Revenue Next Year | $9.63 | $16,320.74 |
| P/E Ratio | $43.33 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.84 | $2.54 |
| 52 Week High | $4.62 | $7.18 |
| Indicator | VTEX | ANNX |
|---|---|---|
| Relative Strength Index (RSI) | 41.69 | 45.25 |
| Support Level | $3.45 | $3.79 |
| Resistance Level | $3.74 | $4.36 |
| Average True Range (ATR) | 0.07 | 0.24 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 28.57 | 77.61 |
Vtex provides a software-as-a-service digital commerce platform for enterprise brands and retailers. Its platform enables customers to execute their commerce plan, including building online stores, integrating and managing orders across channels, and creating marketplaces to sell products from third-party vendors. The VTEX platform is designed to be composable and complete, enabling its customers to seamlessly implement, optimize, test, and expand both B2C and B2B digital experiences. It generates maximum revenues from Brazil followed by Latin America and the rest of the world.
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502, for Oral small molecule; and ANX009, for systemic autoimmune diseases.